Nervous System News and Research

Latest Nervous System News and Research

Researchers analyze role of gender in treatment and outcome of patients with MMD

Moyamoya disease is an uncommon, progressive cerebrovascular disease in which the main arteries feeding the brain (the intracranial internal carotid arteries/ICA and Circle of Willis) are narrowed or occluded on both sides, reducing blood flow to the brain. This causes transient episodes of reversible stroke with loss of neurologic function in the form of weakness of a limb, sensory disturbances, epileptic seizures or headaches.

5 May 2010

Ventral striatum plays important role in circuitry of reward-oriented behavior: Researchers

An estimated 26.2 percent of Americans ages 18 and older - about one in four adults - suffer from a diagnosable mental disorder every year, which equates to approximately 57.7 million adults. Severe psychiatric illness affects a much smaller number of people - about 6 percent, or 1 in 17. Worldwide, an estimated 340 million people suffer from an episode of major depression every year.

5 May 2010

StemCells first-quarter total revenue up 307%

StemCells, Inc., a leading stem cell technology company with the dual focus of novel therapeutics and innovative research products, today reported financial results for the first quarter ended March 31, 2010 and recent business highlights.

5 May 2010

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Alvine Pharmaceuticals, Inc., today announced the reporting of scientific data on the performance of its lead compound, ALV003, in a gastric simulation model. The data were presented at the 2010 Digestive Disease Week (DDW) meeting held in New Orleans, Louisiana.

5 May 2010

Gamma Knife stereotactic radiosurgery effective for patients with large acoustic neuromas: Study

A new Mayo Clinic study has found that Gamma Knife stereotactic radiosurgery is a successful treatment for the majority of patients who have large acoustic neuromas (also known as vestibular schwannoma or neurolemmoma). Gamma Knife surgery already is an accepted treatment for small to medium-sized acoustic neuromas.

5 May 2010

Alexza Pharmaceuticals announces filing of universal shelf registration statement with SEC

Alexza Pharmaceuticals, Inc. announced today that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow the Company to sell, from time to time, up to $75 million of its common stock, preferred stock, debt securities and/or warrants, either individually or in units, in one or more offerings.

5 May 2010

Research analyzes clinical connection of NPH to AD

Normal Pressure Hydrocephalus is a neurological condition which typically affects adults ages 55 and older. This condition was first described in the 1960s as a triad of gait disturbance, dementia, and bladder incontinence. The ventricles of the brain appear enlarged although the cerebrospinal fluid pressure remains normal.

5 May 2010

Additional pivotal Phase 3 trial data for MoxDuo IR released

QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application submission with the United States Food and Drug Administration, this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.

5 May 2010

Vanda reports total revenue of $12.4 million for first-quarter 2010

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2010.

4 May 2010

Researchers explore role of ECoG measurement to improve brain mapping technology

Epilepsy and seizures affect nearly 3 million Americans of all ages, with 200,000 new cases of seizures and epilepsy occurring each year. Epilepsy surgery may be performed in patients who have seizures associated with structural brain abnormalities, such as benign brain tumors and cortical dysplasia, malformations of blood vessels, the genetic disorder tuberous sclerosis, and strokes.

4 May 2010

New study shows people with BAV more likely to have brain aneurysms

A new study shows that people with a common heart defect may also be more likely to have brain aneurysms. The study is published in the May 4, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

4 May 2010

UCB, IBDWG announce recipients of 2010 Research Awards in IBD for GI Fellows

UCB and the Inflammatory Bowel Disease Working Group today announced the five recipients of the 2010 Research Awards in Inflammatory Bowel Disease for Gastroenterology Fellows, each of whom will receive a one-year $40,000 research grant for their original clinical or basic research.

4 May 2010

Novel combined immunotherapy promising for treatment of malignant brain tumors

A new Phase I clinical trial conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute in Los Angeles shows that two innovative treatment approaches may safely be combined to treat patients with highly aggressive, malignant brain tumors called gliomas. The results suggest that combining the two therapies might boost their effectiveness and supports the pursuit of additional studies on this approach to treating these tumors.

4 May 2010

Researchers study relationship between insurance status and head injury patient transfer

The Emergency Medical Treatment & Labor Act was enacted in 1986 to provide access to emergency medical care and transfer for all patients, regardless of immigration status or ability to pay.

4 May 2010

Neural stem cell transplantation promising for Batten disease

Neuronal Ceroid Liposfuscinosis (NCL), often referred to as Batten disease, is a rare and fatal neurodegenerative disorder that afflicts infants and young children. NCL is caused by a deficiency of a lysosomal enzyme, and is a relatively rare disease, affecting an estimated 2 to 4 of every 100,000 babies born in the U.S. Although NCLs are classified as rare diseases, they often affect more than one child in families that carry the defective gene, and tragically, are always fatal.

4 May 2010

Researchers evaluate efficacy of GKRS in patients with pituitary adenoma

In 2009, it was estimated that a total of 22,070 new cases of brain and other CNS tumors were diagnosed. Pituitary adenomas represent one of the most common brain tumors. Large studies report that approximately 10-20 percent of the population harbors a pituitary tumor. According to the Central Brain Tumor Registry of the United States, 13.4 percent of all brain and CNS tumors diagnosed in 2009 were located in the pituitary.

4 May 2010

Sepracor issued FDA Complete Response Letter for STEDESA NDA

Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.

4 May 2010

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.

3 May 2010

Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010

Penwest Pharmaceuticals Co. today announced its financial results for the first quarter ended March 31, 2010. Compared with the first quarter of 2009, first quarter 2010 revenues increased sharply to $8.8 million, and operating expenses decreased by 20%. The Company had net income of $0.12 per share for the first quarter of 2010.

3 May 2010

AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010

AVANIR Pharmaceuticals, Inc. today reported unaudited financial results for the three and six months ended March 31, 2010.

3 May 2010

Nervous System News and Research

Latest Nervous System News and Research

Researchers analyze role of gender in treatment and outcome of patients with MMD

Ventral striatum plays important role in circuitry of reward-oriented behavior: Researchers

StemCells first-quarter total revenue up 307%

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Gamma Knife stereotactic radiosurgery effective for patients with large acoustic neuromas: Study

Alexza Pharmaceuticals announces filing of universal shelf registration statement with SEC

Research analyzes clinical connection of NPH to AD

Additional pivotal Phase 3 trial data for MoxDuo IR released

Vanda reports total revenue of $12.4 million for first-quarter 2010

Researchers explore role of ECoG measurement to improve brain mapping technology

New study shows people with BAV more likely to have brain aneurysms

UCB, IBDWG announce recipients of 2010 Research Awards in IBD for GI Fellows

Novel combined immunotherapy promising for treatment of malignant brain tumors

Researchers study relationship between insurance status and head injury patient transfer

Neural stem cell transplantation promising for Batten disease

Researchers evaluate efficacy of GKRS in patients with pituitary adenoma

Sepracor issued FDA Complete Response Letter for STEDESA NDA

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010

AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010

Everything you need to know about epilepsy eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Nervous System News and Research

Latest Nervous System News and Research

Everything you need to know about epilepsy eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in